Our pharmaceuticals business revolves around Otsuka Pharmaceutical Co., Ltd., which aspires to create innovative pharmaceuticals focusing primarily on the areas of central nervous system, oncology and cardiovascular, and Taiho Pharmaceutical Co., Ltd., which is a leading company in the field of anticancer therapies. Otsuka Pharmaceutical Factory Inc. is largely responsible for the parenteral nutrition business with a view to develop this area on a global basis.
Otsuka Group is also concentrating on developing its diagnostics and medical devices businesses, with a long-term perspective on future market growth, to provide comprehensive health care services ranging from diagnosis through to treatment of diseases.
Otsuka Pharmaceutical has been actively developing pharmaceuticals for the global market ever since the establishment of a research and development division in 1971. The company is constantly focused on resolving medical issues associated with curing disease and improving the quality of life (QOL), aspiring to develop innovative pharmaceuticals to aid in treating disorders of the central nervous system; cancer; cardiovascular, gastrointestinal and respiratory ailments; infectious diseases; and in the areas of ophthalmology and dermatology. New drug development is also progressing in the fields of aquaretics, tuberculosis, epilepsy and rheumatism.
Based on a global strategy for the development and commercialization of pharmaceuticals, preclinical research is conducted in Japan, the US and China, while clinical development occurs mainly in Japan, the US, Europe and Asia, utilizing an extensive network of research facilities both within and outside Japan for global research and development.
Taiho Pharmaceutical conducts pharmaceutical research and development specializing in the areas of oncology, allergy/immunology and urology, and has four centers responsible for drug development: Drug Discovery Research Center, Tokushima Research Center, CMC Research Center and the Clinical Research and Development Center. In addition, in August of 2009, Taiho Pharmaceutical acquired the Banyu Pharmaceutical’s Tsukuba Research Institute as a base for developing anticancer agents. These research centers, boasting high-level specialist knowledge and technologies, are organically linked, and continue to rise to the challenge of researching and developing innovative new drugs.
Otsuka Pharmaceutical Factory was established in Naruto City, Tokushima Prefecture where the Otsuka Group has its origins, and is fully committed to preclinical research and new product development. Otsuka Pharmaceutical Factory is conducting research and development of parenteral solutions in clinical nutrition business area, developing pharmaceutical manufacturing technology for contract services business area, and researching and developing disinfectants adhesion inhibitors and organ storage solutions in our new business area.
